RecruitingNCT06439069
BMI-Driven Tolerability and Efficacy of Entresto in Heart Failure Patients
Sponsor
Lithuanian University of Health Sciences
Enrollment
340 participants
Start Date
Aug 10, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to determine if patients with higher BMI can tolerate higher doses of Entresto (sacubitril/valsartan) and experience better symptomatic and functional outcomes compared to patients with lower BMI.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Adults aged 18 and older
- Diagnosed with heart failure with reduced ejection fraction (HFrEF) (LVEF ≤ 35%)
- Naïve to Entresto therapy or willing to switch from previous ACE inhibitor/ARB therapy
- Ability to provide informed consent
Exclusion Criteria5
- Severe renal or hepatic impairment (e.g., eGFR \< 30 mL/min/1.73m², severe liver disease)
- History of angioedema
- Pregnant or breastfeeding women
- Patients with malignancies or other severe comorbid conditions
- Non-compliance with medication regimen
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06439069
Related Trials
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
NCT0724708425 locations
Mind Your Heart-II
NCT054311921 location
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations